Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age.

Trial Profile

Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Sunitinib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jul 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 29 Jun 2012 Planned end date changed from 1 Apr 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 28 Apr 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-007553-31).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top